BG Medicine said last week that it filed a 510(k) submission with the US Food & Drug Administration for an automated version of its BGM Galectin-3 heart failure test to be run on Abbott Laboratories' Architect platform.
Thermo Fisher Scientific said this week it has acquired the exclusive rights from diagnostics firm Nephromics to use placental growth factor protein as a biomarker for the diagnosis of preeclampsia and eclampsia.
AmberGen is developing a microbead-based, multiplexed, in vitro pediatric allergy test. The diagnostic is designed to enable the detection of multiple allergen-specific IgE antibodies in blood, according to a company executive.
By Tony Fong NEW YORK (GenomeWeb News) – As companion diagnostics gain acceptance within the pharmaceutical sector and next-generation sequencing progresses toward clinical applications, Siemens is seeking a bigger role in the genomics space.